Differential Expression And Significance Of STOML2 Protein In Prostate Cancer And Benign Prostatic Hyperplasia

Objectives Experimental study to detect the expression of STOML2 protein in prostate cancer and benign prostatic hyperplasia tissue, and preliminary study on the role of STOML2 protein in the occurrence and development of prostate cancer.Methods Immunohistochemical method is used to detect the pathological sections of 30 cases of prostate cancer and 30 cases of benign prostatic hyperplasia. The expression of STOML2 protein is detected by Fisher's exact probability method. To collate and group the clinical data of patients with prostate cancer. The expression of STOML2 protein is detected in the grouping of clinical parameters. The correlation between STOML2 protein and the grouping of clinical parameters is detected by Rank test. Protein and total RNA were extracted from 4 cases of prostate cancer and 4 cases of benign prostatic hyperplasia. STOML2 protein and m RNA content in prostate cancer and benign prostatic hyperplasia specimens were detected by Western blot and Q-PCR assay, and Independent sample t test is used for data statistics.Results In 30 cases of prostate cancer patients, the expression of STOML2 protein has 24 cases of positive expression and 6 cases of negative expression. The positive expression rate is 80%(24/30). In 30 cases of patients with benign prostatic hyperplasia, the expression of STOML2 protein has 4 cases of positive expression and 26 cases of negative expression. The positive expression rate is 13.3%(4/30). The statistical analysis found that the expression of STOML2 protein is statistically significant in the prostate cancer group and benign prostatic hyperplasia group(P<0.05). The positive expression of STOML2 protein in distant metastasis group has 17 cases and 1 case is negative expression. The positive expression rate is 94.4%(17/18). There are 7 cases of positive expression and 5 cases of negative expression in the distant metastasis. The positive expression rate is 58.3%(7/12). The expression of STOML2 protein has statistically significant in the distant metastasis group through statistical analysis(P<0.05). STOML2 protein expression does not have statistically significant in prostate cancer patients age group, preoperative PSA score group, prostate volume group, Gleason score group, clinical stage group and lymph node metastasis group(P>0.05). The STOML2 protein content is(1.67 + 0.36) in the tissues of the patients with prostate cancer, and the STOML2 protein content was(0.80 + 0.19) in patients with benign prostatic hyperplasia. The difference of STOML2 protein in prostate cancer group and benign prostatic hyperplasia group has statistically significant by statistical analysis(P<0.05). The m RNA content of STOML2 gene is(1.97 + 0.67) in patients with prostate cancer tissue samples, and the m RNA content of STOML2 gene is(0.63 + 0.32) in patients with benign prostatic hyperplasia tissue samples. The m RNA content of STOML2 gene has statistically significant difference between the prostate and benign prostatic hyperplasia group through statistical analysis(P<0.05).Conclusions The positive expression rate of STOML2 in prostate cancer was higher than that in benign prostatic hyperplasia, and the protein content and m RNA content of STOML2 in prostate cancer specimens were higher than those in benign prostatic hyperplasia tissues. These results suggest that STOML2 protein is highly expressed in prostate cancer and its content is increased. STOML2 protein is closely related to the occurrence of prostate cancer. The expression of STOML2 protein was correlated with the metastasis of prostate cancer patients. This means that there is a positive correlation between the expression of STOML2 protein and the distant metastasis. This suggests that STOML2 protein expression increased with the development of prostate cancer patients, and STOML2 protein plays an important role in the development of prostate.